{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/97776"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/97776","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Epigenetic and expression-based modifications of depression-relevant genes as peripheral biomarkers for treatment-resistant depression and major depressive disorder","abstract":"Mechanisms contributing to treatment resistant depression (TRD) and major depressive disorder (MDD) are poorly understood. Identifying peripheral biomarkers in an easily accessible tissue, such as whole blood, will enhance the mechanistic understanding of these disorders and could potentially establish targets for personalized treatment development. It has been shown that CpG methylation-based epigenetic modifications in the brain are associated with stress-related phenotypes. Therefore, the first portion of the current study sought to identify CpG methylation-based peripheral biomarkers of TRD concordant with brain CpG methylation in the rat, in a hormone-induced model of TRD. Many factors, both environmental and biological, can alter CpG methylation in blood and/or brain tissues in eukaryotes. This differential CpG methylation is a well-documented functional mechanism by which genes are differentially expressed. Depending on the specific gene, this functional alteration of expression can have downstream physiological and phenotypic effects. Taking into account the need to identify peripheral biomarkers of MDD in humans, the second portion of the current study sought to identify the association between lifetime MDD diagnosis status and peripheral, blood-derived methylation and expression. Finally, supplementary analyses of publically available datasets highlight the association between neuronal CpG methylation and lifetime MDD diagnosis status and using a cohort of deceased subjects with balanced prevalence of lifetime MDD cases and “healthy” controls, as well as intra-subject brain and blood CpG methylation correlations in “healthy” controls. The current study identified one salient peripheral biomarker for TRD that is concordant in CNS tissue, as well as one potential peripheral biomarker for MDD. In the TRD rat model, the first CpG site upstream of the transcription start site (TSS) in the promoter region of Slc6a3 was differentially methylated between case and control group animals in both mPFC and whole blood. Second, using blood drawn from human participants from the Detroit Neighborhood Health Study, SLC6A4 mRNA expression approached a significant association with lifetime MDD diagnosis status. Efforts to elucidate additional peripheral biomarkers should continue to expand to include polygenic CpG methylation measurements in multiple tissues.","abstract_html":"Mechanisms contributing to treatment resistant depression (TRD) and major depressive disorder (MDD) are poorly understood. Identifying peripheral biomarkers in an easily accessible tissue, such as whole blood, will enhance the mechanistic understanding of these disorders and could potentially establish targets for personalized treatment development. It has been shown that CpG methylation-based epigenetic modifications in the brain are associated with stress-related phenotypes. Therefore, the first portion of the current study sought to identify CpG methylation-based peripheral biomarkers of TRD concordant with brain CpG methylation in the rat, in a hormone-induced model of TRD. Many factors, both environmental and biological, can alter CpG methylation in blood and/or brain tissues in eukaryotes. This differential CpG methylation is a well-documented functional mechanism by which genes are differentially expressed. Depending on the specific gene, this functional alteration of expression can have downstream physiological and phenotypic effects. Taking into account the need to identify peripheral biomarkers of MDD in humans, the second portion of the current study sought to identify the association between lifetime MDD diagnosis status and peripheral, blood-derived methylation and expression. Finally, supplementary analyses of publically available datasets highlight the association between neuronal CpG methylation and lifetime MDD diagnosis status and using a cohort of deceased subjects with balanced prevalence of lifetime MDD cases and “healthy” controls, as well as intra-subject brain and blood CpG methylation correlations in “healthy” controls. The current study identified one salient peripheral biomarker for TRD that is concordant in CNS tissue, as well as one potential peripheral biomarker for MDD. In the TRD rat model, the first CpG site upstream of the transcription start site (TSS) in the promoter region of Slc6a3 was differentially methylated between case and control group animals in both mPFC and whole blood. Second, using blood drawn from human participants from the Detroit Neighborhood Health Study, SLC6A4 mRNA expression approached a significant association with lifetime MDD diagnosis status. Efforts to elucidate additional peripheral biomarkers should continue to expand to include polygenic CpG methylation measurements in multiple tissues.","abstract_has_math":false,"creators":["Pfeiffer, John R"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"M.A.","degree_level":"Thesis","degree_discipline":"Psychology","degree_department":null,"school":null,"contributors":["Uddin, Monica","Zhao, Dave"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017-08-10T20:33:23Z","date_published":"2017-08-10T20:33:23Z","updated_at":"2026-07-22T22:24:34Z","subjects":["Methylation","Expression","Blood","Brain","Human","Rat","Major depressive disorder","Treatment-resistant depression","Peripheral biomarker"],"languages":["en"],"rights":["Copyright 2017 John Pfeiffer"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/97776","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Uddin, Monica","Zhao, Dave"]},{"key":"dc:creator","label":"Author","values":["Pfeiffer, John R"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2017-08-10T20:33:23Z","2019-08-11T09:15:17Z","2017-04-26","2017-05"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Psychology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.A."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Methylation","Expression","Blood","Brain","Human","Rat","Major depressive disorder","Treatment-resistant depression","Peripheral biomarker"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2017 John Pfeiffer"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/97776"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Mechanisms contributing to treatment resistant depression (TRD) and major depressive disorder (MDD) are poorly understood. Identifying peripheral biomarkers in an easily accessible tissue, such as whole blood, will enhance the mechanistic understanding of these disorders and could potentially establish targets for personalized treatment development. It has been shown that CpG methylation-based epigenetic modifications in the brain are associated with stress-related phenotypes. Therefore, the first portion of the current study sought to identify CpG methylation-based peripheral biomarkers of TRD concordant with brain CpG methylation in the rat, in a hormone-induced model of TRD. Many factors, both environmental and biological, can alter CpG methylation in blood and/or brain tissues in eukaryotes. This differential CpG methylation is a well-documented functional mechanism by which genes are differentially expressed. Depending on the specific gene, this functional alteration of expression can have downstream physiological and phenotypic effects. Taking into account the need to identify peripheral biomarkers of MDD in humans, the second portion of the current study sought to identify the association between lifetime MDD diagnosis status and peripheral, blood-derived methylation and expression. Finally, supplementary analyses of publically available datasets highlight the association between neuronal CpG methylation and lifetime MDD diagnosis status and using a cohort of deceased subjects with balanced prevalence of lifetime MDD cases and “healthy” controls, as well as intra-subject brain and blood CpG methylation correlations in “healthy” controls. The current study identified one salient peripheral biomarker for TRD that is concordant in CNS tissue, as well as one potential peripheral biomarker for MDD. In the TRD rat model, the first CpG site upstream of the transcription start site (TSS) in the promoter region of Slc6a3 was differentially methylated between case and control group animals in both mPFC and whole blood. Second, using blood drawn from human participants from the Detroit Neighborhood Health Study, SLC6A4 mRNA expression approached a significant association with lifetime MDD diagnosis status. Efforts to elucidate additional peripheral biomarkers should continue to expand to include polygenic CpG methylation measurements in multiple tissues.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2019-05-01","The student, John Pfeiffer, accepted the attached license on 2017-04-24 at 14:43.","The student, John Pfeiffer, submitted this Thesis for approval on 2017-04-25 at 15:32.","This Thesis was approved for publication on 2017-04-26 at 13:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #11015 on 2017-08-10 at 15:06:57","Made available in DSpace on 2017-08-10T20:33:23Z (GMT). No. of bitstreams: 2 PFEIFFER-THESIS-2017.pdf: 813331 bytes, checksum: 9733f9af26df2aec87d87a08de33760b (MD5) LICENSE.txt: 4210 bytes, checksum: b92acb3ff6973a1c1563628390cb890c (MD5) Previous issue date: 2017-04-26","Embargo set by: Colleen Fallaw for item 102829 Lift date: 2019-08-10T21:27:21Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 102829 on 2019-08-11T09:15:17Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Epigenetic and expression-based modifications of depression-relevant genes as peripheral biomarkers for treatment-resistant depression and major depressive disorder"]}]}],"canonical_facts":{"dc:contributor":["Uddin, Monica","Zhao, Dave"],"dc:creator":["Pfeiffer, John R"],"dc:date":["2017-08-10T20:33:23Z","2019-08-11T09:15:17Z","2017-04-26","2017-05"],"dc:description":["Mechanisms contributing to treatment resistant depression (TRD) and major depressive disorder (MDD) are poorly understood. Identifying peripheral biomarkers in an easily accessible tissue, such as whole blood, will enhance the mechanistic understanding of these disorders and could potentially establish targets for personalized treatment development. It has been shown that CpG methylation-based epigenetic modifications in the brain are associated with stress-related phenotypes. Therefore, the first portion of the current study sought to identify CpG methylation-based peripheral biomarkers of TRD concordant with brain CpG methylation in the rat, in a hormone-induced model of TRD. Many factors, both environmental and biological, can alter CpG methylation in blood and/or brain tissues in eukaryotes. This differential CpG methylation is a well-documented functional mechanism by which genes are differentially expressed. Depending on the specific gene, this functional alteration of expression can have downstream physiological and phenotypic effects. Taking into account the need to identify peripheral biomarkers of MDD in humans, the second portion of the current study sought to identify the association between lifetime MDD diagnosis status and peripheral, blood-derived methylation and expression. Finally, supplementary analyses of publically available datasets highlight the association between neuronal CpG methylation and lifetime MDD diagnosis status and using a cohort of deceased subjects with balanced prevalence of lifetime MDD cases and “healthy” controls, as well as intra-subject brain and blood CpG methylation correlations in “healthy” controls. The current study identified one salient peripheral biomarker for TRD that is concordant in CNS tissue, as well as one potential peripheral biomarker for MDD. In the TRD rat model, the first CpG site upstream of the transcription start site (TSS) in the promoter region of Slc6a3 was differentially methylated between case and control group animals in both mPFC and whole blood. Second, using blood drawn from human participants from the Detroit Neighborhood Health Study, SLC6A4 mRNA expression approached a significant association with lifetime MDD diagnosis status. Efforts to elucidate additional peripheral biomarkers should continue to expand to include polygenic CpG methylation measurements in multiple tissues.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2019-05-01","The student, John Pfeiffer, accepted the attached license on 2017-04-24 at 14:43.","The student, John Pfeiffer, submitted this Thesis for approval on 2017-04-25 at 15:32.","This Thesis was approved for publication on 2017-04-26 at 13:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #11015 on 2017-08-10 at 15:06:57","Made available in DSpace on 2017-08-10T20:33:23Z (GMT). No. of bitstreams: 2 PFEIFFER-THESIS-2017.pdf: 813331 bytes, checksum: 9733f9af26df2aec87d87a08de33760b (MD5) LICENSE.txt: 4210 bytes, checksum: b92acb3ff6973a1c1563628390cb890c (MD5) Previous issue date: 2017-04-26","Embargo set by: Colleen Fallaw for item 102829 Lift date: 2019-08-10T21:27:21Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 102829 on 2019-08-11T09:15:17Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/97776"],"dc:language":["en"],"dc:rights":["Copyright 2017 John Pfeiffer"],"dc:subject":["Methylation","Expression","Blood","Brain","Human","Rat","Major depressive disorder","Treatment-resistant depression","Peripheral biomarker"],"dc:title":["Epigenetic and expression-based modifications of depression-relevant genes as peripheral biomarkers for treatment-resistant depression and major depressive disorder"],"dc:type":["text"],"thesis:degree_discipline":["Psychology"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.A."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:34Z"}